By Hariprasad Chandran
The imposition of U.S. pharmaceutical tariffs threatens to disrupt India’s drug exports and global health, as the U.S. administration launched a Section 232 investigation into pharmaceutical imports in April, citing national security concerns over reliance on foreign-made medicines. This move could result in tariffs ranging from 25% to 200% on generics, branded drugs, active pharmaceutical ingredients (APIs), and packaging materials. While a final decision is pending, signals from Washington indicate action later this year, causing significant apprehension within India’s pharmaceutical industry.
India, a critical player in the global pharmaceutical landscape, supplies nearly 40% of the generics consumed in the U.S. The proposed tariffs could severely undermine India’s annual pharma exports to the U.S., valued at $9-10 billion, and have far-reaching consequences, including increased American drug prices and diminished global access to affordable medicines.
India’s Pharma Industry: Resilient, Yet Vulnerable
For decades, India has earned its reputation as the “world’s pharmacy” by providing life-saving treatments on a massive scale, from HIV antiretrovirals in Africa to cancer drugs in the U.S.. Leading Indian pharmaceutical companies such as Sun Pharma, Cipla, Dr. Reddy’s, Lupin, and Aurobindo have established reliable supply pipelines for high-quality, cost-effective medicines. However, the inherently thin margins on generic drugs leave these companies with minimal capacity to absorb substantial tariffs.
Industry leaders have voiced grave concerns. Cipla CEO Umang Vohra warned that establishing U.S.-based manufacturing to offset such duties is too risky given current policy uncertainty. Similarly, Sun Pharma’s Dilip Shanghvi stated that large-scale U.S. manufacturing is not economically viable. Smaller Indian firms, already contending with high compliance costs and price erosion, may be compelled to withdraw from the U.S. market entirely.
$9-10 Billion in Exports at Immediate Risk
India’s annual pharmaceutical exports to the U.S. amount to approximately $9-10 billion, constituting almost a third of its total global pharma exports. These tariffs could lead to a 6-12% erosion of these exports, with a particularly severe impact on generics and APIs. This comes at a critical juncture when the U.S. is already grappling with record-high drug shortages, with over 300 medicines currently listed in short supply. The imposition of tariffs would undoubtedly exacerbate this crisis, forcing U.S. patients to shoulder higher costs while slowing treatment access.
Beyond Trade: A Dire Threat to Global Health
The U.S. administration frames these measures as an effort to reduce import dependence. However, past experiences, such as the 25% duties imposed on Chinese APIs, only worsened supply bottlenecks. Furthermore, domestic manufacturing initiatives, like Eli Lilly’s new facilities, are years away from achieving the necessary scale to meet demand. Consequently, American patients remain reliant on imports from countries like India and China.
While the U.S. contemplates protectionist measures, India and China are actively diversifying their pharmaceutical export markets across Europe, Africa, and Latin America, where demand for affordable supply chains is rapidly increasing. The U.S. risks ceding its influence in the global pharmaceutical trade, while its own citizens bear the brunt of “economic nationalism” through higher drug costs.
Four Critical Risks for India and the World
Revenue Hit: Pharma exports to the U.S. could see multi-billion-dollar declines. This directly threatens India’s pharmaceutical industry, which heavily relies on the U.S. market.
Market Retreat: Mid-sized Indian firms may pull out of the U.S. market entirely. Their thin margins and high compliance costs make absorbing steep tariffs unfeasible.
Stalled Growth: Investments in manufacturing and R&D could be delayed or diverted. This impacts India’s long-term pharmaceutical growth and hinders global innovation in affordable medicine development.
Access Crisis: Drug shortages could worsen, especially in low and middle-income nations dependent on Indian supply. India’s role as the “world’s pharmacy” is crucial for global health, making disruption catastrophic for vulnerable populations.
India’s Imperative: A Strategic and Proactive Response
India must adopt a coordinated and strategic response to this escalating threat.
Aggressive Diplomatic Engagement and Multilateral Leverage: Initiate high-level diplomatic discussions with Washington, emphasizing severe implications for U.S. patients and global health security. Leverage the World Trade Organization (WTO) and other multilateral forums, potentially initiating dispute settlement proceedings against tariffs as trade barriers. Collaborating with nations reliant on Indian pharmaceuticals can build collective opposition.
Accelerated Market Diversification: Intensify efforts to diversify pharmaceutical export destinations beyond the U.S.. Deepen ties with the EU, ASEAN bloc, African nations, and Latin American countries, where demand for affordable pharmaceuticals is surging. Regulatory alignment with the EU, for instance, could streamline market access.
Strengthening API Self-Reliance with Enhanced PLI Scheme: Rigorously accelerate and expand the Production Linked Incentive (PLI) scheme to reduce dependence on China for Active Pharmaceutical Ingredients (APIs). This involves incentivizing domestic manufacturing, fostering innovation in API production, and securing raw material sourcing within India. Past experience shows Chinese API duties worsened bottlenecks, highlighting the need for true self-reliance.
Strategic Alliance with U.S. Stakeholders: Proactively build alliances with U.S. patient advocacy groups, hospitals, insurers, and healthcare providers. Provide them with data on tariff impacts to mobilize domestic opposition within the U.S.. Organizations like the Association for Accessible Medicines (AAM) can be key collaborators.
*Hariprasad Chandran is a distinguished pharmaceutical professional with over 16 years of extensive experience in global pharmacovigilance and healthcare operations